Bluejay Diagnostics Inc (BJDX)
0.5499
-0.08
(-12.02%)
USD |
NASDAQ |
Apr 24, 16:00
0.55
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.478M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -91.33% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.5107 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis. |
| URL | https://www.bluejaydx.com |
| Investor Relations URL | https://ir.bluejaydx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | N/A |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Nov. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis. |
| URL | https://www.bluejaydx.com |
| Investor Relations URL | https://ir.bluejaydx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | N/A |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Nov. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |